BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alere Inc. (ALR) Reports Employment Inducement Award Pursuant to NYSE Rule 303A.08


1/7/2013 11:06:30 AM

WALTHAM, Mass., Jan. 4, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company") announced today, pursuant to NYSE Rule 303A.08, that it granted an employment inducement award to Namal Nawana, the Company's new Chief Operating Officer, as part of his previously disclosed compensation package. On December 12, 2012, the Company announced the appointment of Mr. Nawana to serve as its new COO, effective December 30, 2012.

As of December 30, 2012, Mr. Nawana was granted Restricted Stock Units (RSUs) in Alere Inc. as follows: 5,000 RSUs to vest 1 year after the grant date, 5,000 RSUs to vest 2 years after the grant date, and 100,000 RSUs to vest 3 years after the grant date. These RSUs were granted as an employment inducement award outside of Alere Inc.'s current shareholder approved stock options and incentive plans pursuant to NYSE Rule 303A.08. For the further details regarding Mr. Nawana's employment and compensation, please see the Company's Current Report on Form 8-K filed December 12, 2012 with the Securities and Exchange Commission.

About Alere Inc.
By developing new capabilities in near-patient diagnosis, monitoring and health management, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology, diabetes, oncology and women's health. Alere is headquartered in Waltham, Massachusetts.

For additional information on Alere, please visit www.alere.com

SOURCE Alere Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES